All Blogs
Oct 15, 2026
B. Braun Receives Medicare Payment Approval for Peripheral Nerve Block Devices; FDA Approves Providence Medical’s CORUS PCSS 3D-T Spinal Device; PurMinds Enters Clinical Validation Collaboration with SpectroChip and Taiwan-Based Hospital; MemorialCare Leads South Los Angeles County in Robotic-Assisted Shoulder Replacement Technology; Clinical Study Demonstrates the Potential of Home-Based Diuretic Delivery for Heart Failure; VIVA 2026 Highlights New Clinical Trial Results
B. Braun Peripheral Nerve Block Devices Approved for Separate Medicare Payment Under the NOPAIN Act On 14 October 2026, B. Braun Medical announced that the U.S. Centers for Medicare and Medicaid Services had approved its Stimuplex Single-Shot Nerve Block Needles as qualifying non-opioid medical devices und...
Read More...
Oct 14, 2026
Ventricular Assist Devices: The Mechanical Hearts Redefining Advanced Heart Failure Care
Heart failure is one of the most pressing public health challenges of our time. An estimated 64 million people live with it worldwide, and in the United States the number of adults affected is projected to approach 9 million by 2030. For most patients, guideline-directed medications, implantable defibrillators, and...
Read More...
Oct 13, 2026
Efzimfotase Alfa Achieves 17.05-Metre Numerical Improvement Over Placebo in Six-Minute Walk Test; Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Study of AIC468 for BK Virus; Teva’s WELTRUZA Gains FDA Approval for Once-Monthly Treatment of Adult Schizophrenia; Innovent’s SYCUME Meets Primary Endpoint in Phase 3 Inactive Thyroid Eye Disease Trial; Zealand Pharma’s Petrelintide Delivers Positive Topline Results in Phase 2 ZUPREME-2 Trial
Efzimfotase Alfa Shows Numerical Improvement in Six-Minute Walk Distance Versus Placebo in HICKORY Phase III Trial Results from the HICKORY Phase III trial indicated that efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy, did not achieve statistical significance for the primary endpoint ...
Read More...
Oct 16, 2026
siRNA vs. Antisense Oligonucleotides: Which RNA Technology Has Greater Commercial Potential?
Summary siRNA and ASOs are emerging as major RNA-based therapeutic platforms, enabling targeted disease treatment by silencing or modulating gene expression. siRNA holds a commercial advantage in revenue generation and dosing convenience. Marketed siRNA drugs generated approximately $4.2 billion in disclosed...
Read More...
Oct 12, 2026
FGFR Inhibitors: How a Once-Overlooked Target Became Precision Oncology’s Next Big Story
Summary FGFR has evolved into a clinically validated oncology target, progressing from a relatively overlooked pathway to an important biomarker-driven treatment strategy across multiple solid tumors. Cholangiocarcinoma is the leading success story for FGFR-targeted therapy. FGFR2 fusions/rearrangements occu...
Read More...
Oct 09, 2026
JUVMO Enters the Parkinson’s Disease Treatment Arena: How AbbVie’s First-in-Class Drug Stacks Up Against Today’s Treatments and Tomorrow’s Pipeline?
Summary On September 28, 2026, the FDA approved AbbVie’s JUVMO (tavapadon) as the first selective dopamine D1/D5 receptor agonist for adults with Parkinson’s disease, introducing a new dopaminergic approach after decades dominated by levodopa and D2/D3 agonists. The approval was supported by findings from the T...
Read More...
Oct 08, 2026
Okami Medical Secures Expanded Indication for LOBO Vascular Occluder; CraniUS Therapeutics Secures Second FDA 510(k) Clearance in Six Weeks and U.S. Patent for NeuroPASS™ 3; Danaher Accelerates Life Sciences Research with New AI-Powered Autonomous Lab; Aesthetic Brokers Advises SDBotox on Strategic Partnership; BD Advances Peripheral Vascular Innovation with Positive AGILITY Trial Results; Sonorous Neurovascular Secures FDA IDE Approval for Pivotal U.S. Trial of Venous Sinus Stent in Pulsatile Tinnitus
Okami Medical Received Expanded Indication for the LOBO Vascular Occluder On 07 October 2026, Okami Medical received an expanded FDA indication for its LOBO Vascular Occlusion System, extending the device's application from peripheral arterial procedures to peripheral venous embolization. The expanded indication...
Read More...
Oct 07, 2026
Microfluidics: The Tiny Technology Powering the Future of Diagnostics and Life Sciences
Imagine running an entire laboratory on a device the size of a postage stamp. A drop of blood goes in, and minutes later a result comes out, with no centrifuge, no bench full of pipettes and no technician in sight. That is the promise of microfluidics, a field that is quietly reshaping medicine, drug development an...
Read More...
Oct 06, 2026
Vaxcyte Announces Positive Phase 3 Topline Data for VAX-31 from OPUS-1 Trial; CSL and Alentis Partner to Advance Lixudebart for Rare Renal and Hepatic Diseases; Pfizer Announces Positive Repigmentation Results for LITFULO in Nonsegmental Vitiligo; AstraZeneca Completes Equity Investment in Summit Therapeutics; Lilly’s Jaypirca Receives FDA Approval Expansion for Certain Patients with Untreated CLL/SLL; Merck’s Tulisokibart Delivers Positive Phase 2b Results in Moderate-to-Severe Hidradenitis Suppurativa
Vaxcyte Reports Successful Topline Outcomes from Pivotal Phase 3 OPUS-1 Study of VAX-31 Vaxcyte, Inc. reported positive topline findings from OPUS-1, its pivotal Phase 3 trial in adults evaluating the safety, tolerability, and immunogenicity of VAX-31, the company’s next-generation 31-valent pneumococcal conjuga...
Read More...
Oct 05, 2026
CGRP Inhibitors in Migraine: The Breakthrough Class Rewriting How the World Treats Its Most Disabling Headache Disorder
Summary Migraine affects approximately one in seven people globally and remains underdiagnosed and undertreated. Migraine care has shifted from repurposed drugs such as antihypertensives, antidepressants, and anticonvulsants toward mechanism-specific therapies targeting the CGRP pathway. Unlike triptans, ...
Read More...